- Email:
Oligodendrocyte Differentiation Service
Introduction
Microglia maturation relies on neural niche signals and the oligodendrocyte-microglia axis. Creative Biolabs generates high-purity, functionally mature human microglia from iPSCs based on these advances. The company provides physiologically functional microglia with stable phenotypes and consistent inflammatory responses via its niche-specific induction platform. These validated cells support reliable neuro-immunology research, disease modeling, and CNS drug discovery.
Discover How We Can Help-Request a Consultation
Oligodendrocyte Differentiation Service
Oligodendrocytes are the myelinating glia of the central nervous system, responsible for axon myelination, electrical signal transmission, and neuronal protection. Oligodendrocyte loss or dysfunction is closely associated with demyelinating diseases, neurodegenerative disorders, spinal cord injury, and stroke.
Fig.1 The development and intracellular signaling pathway of OPCs.1
Key Features
- Derived from human iPSCs/ESCs under defined, xeno-free, feeder-free conditions
- Optimized small-molecule-driven differentiation for high yield and purity
- Generates mature, functional O4+, O1+, MBP+, PLP+ oligodendrocytes
- Forms compact myelin sheets in vitro and supports myelination models
- Stable batch consistency and excellent reproducibility
Service Content
- Stepwise differentiation from pluripotent stem cells to oligodendrocyte progenitor cells (OPCs)
- Maturation into myelinating oligodendrocytes
- Myelination co-culture system with neurons available
- Quality validation: immunofluorescence, qPCR, Western blot, flow cytometry
- Optional: myelination assay, myelin formation analysis, neurotoxicity testing
Related Diseases & Mechanisms
| Disease | Mechanism Involving Oligodendrocytes |
|---|---|
| Multiple Sclerosis | Immune-mediated demyelination, oligodendrocyte apoptosis |
| Alzheimer's Disease | Myelin breakdown, axonal degeneration, impaired remyelination |
| Parkinson's Disease | Dopaminergic axon demyelination, glial dysfunction |
| Spinal Cord Injury | Demyelination, scar formation, and failed remyelination |
| Pelizaeus-Merzbacher Disease | Congenital myelin synthesis defects, PLP1 mutations |
Applications
- Demyelinating disease modeling and mechanism research
- Myelination repair and remyelination drug screening
- Neuron-glia myelination interaction studies
- Neuroprotection and anti-demyelination therapy development
- Toxicity testing and target validation for CNS drug discovery
Workflow
The process begins with a detailed assessment of your specific research goals—whether you require "resting" M0 microglia or "activated" M1/M2 phenotypes for toxicity screening.
What We Can Offer
At Creative Biolabs, we recognize that every neurological research project has unique biological requirements. We provide a highly customizable Microglia Differentiation platform that scales from initial discovery to high-throughput screening applications.
Customized Differentiation Protocols
Tailored induction pathways to generate specific microglial states (e.g., DAM or Homeostatic M0) based on your target disease pathology.
Scalable Production Capabilities
Integrated one-stop differentiation services from laboratory-scale pilot batches to large-scale industrial bioreactor production for global screening campaigns.
Advanced Genetic Engineering
Optimization of codon usage and CRISPR-mediated gene editing to generate reporter lines or knockout microglia for mechanism-of-action studies.
Rigorous Quality Assurance
Documentation quality and procedures of cell origin are assessed and approved by our qualified QA service, ensuring full traceability and stability across cell banks.
Process Analytical Techniques (PAT)
Implementation of Quality-by-Design (QbD) and strict aseptic verification procedures throughout the differentiation and maturation phases.
All-side Characterization
High-standard quality control tools used to quantify marker expression (TMEM119, P2RY12) and evaluate functional quality via HACCP-inspired risk management.
Diverse Culture Modes
Support for batch, fed-batch, or continuous culture modes in 3D-organoid or 2D-monolayer systems to maximize biological relevance and yield.
Case Study
Experience the Creative Biolabs Advantage-Get a Quote Today
FAQs
Q: How do you verify the maturity of the differentiated microglia?
A: We use a combination of qPCR for homeostatic markers (CX3CR1, P2RY12), flow cytometry for surface markers, and functional assays like bead phagocytosis and chemotaxis.
Q: Can you differentiate microglia from patient-specific iPSC lines?
A: Yes, we can utilize your provided iPSC lines or select from our extensive bank of disease-modeled lines to create patient-specific neuro-immunology models.
Q: What is the purity level of the final cell population?
A: Our optimized protocols consistently yield populations that are >90% IBA1/CD11b positive, with minimal contamination from other myeloid lineages.
Q: Are the cells suitable for co-culture with neurons or oligodendrocytes?
A: Yes. Our cells are matured in media designed to be compatible with common neural co-culture systems to study complex cell-cell interactions.
Q: How are the cells shipped?
A: We primarily ship cryopreserved vials in liquid nitrogen vapor shippers, though live culture shipping is available for certain geographic regions.
Creative Biolabs offers a suite of Microglia Differentiation services designed to remove the biological bottlenecks in your CNS research. By providing high-purity, functionally validated, and niche-primed microglia, we empower your team to focus on discovery rather than cell line development.
Contact Our Team for More Information and to Discuss Your Project
Reference
- Xiang, Qiong, et al. "Oligodendrocyte: Development, Plasticity, Biological Functions, Diseases, and Therapeutic Targets." MedComm 7.2 (2026): e70618.. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1002/mco2.70618.
For Research Use Only. Not For Clinical Use.